Analysis of 2 phase 3 clinical trials evaluating the safety/efficacy of glecaprevir/pibrentasvir in people with HCV coinfected with HIV-1 found an overall sustained virologic response of 98% at week 12 of treatment in those with or without cirrhosis.
Once-daily single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in adults who have virologic suppression of HIV-1 infection has a high efficacy and safety profile.
Incidence of body fat redistribution/accumulation, pancreatic disorders, musculoskeletal disorders, IRIS, severe systemic rash, and HSR did not differ among common prescribed antiretrovirals.
A combination single tablet once-a-day regimen of doravirine/lamivudine/tenofovir disoproxil fumarate demonstrated non-inferiority and no significant adverse events when compared with continuation of established antiretroviral therapy in adults infected with HIV-1.
The week 96 results of the DRIVE-AHEAD phase 3 noninferiority trial support noninferiority of doravirine to efavirenz in treatment-naive adults with HIV-1.
Children who are HIV-exposed, but uninfected, demonstrated a higher risk of adverse neurologic events during infancy and early childhood associated with ART exposure in-utero.
Number of HIV diagnoses in those aged 13 to 29 four times higher than those age 50 years or older.
A flexible, scalable intervention increases antiretroviral therapy and medication-assisted treatment use while reducing mortality in people who inject drugs.
Antiretroviral therapy initiation within 4 weeks of a cryptococcal meningitis diagnosis in PLWHIV appears to be associated with a higher mortality risk.
A recent meta-analysis and literature review found moderate evidence supporting an association between pain outcomes in people with HIV and several psychosocial factors.
Tenofovir diphosphate in dried blood spots was strongly associated with virologic suppression in those living with HIV on TDF-based therapies.
Exposure to abacavir is associated with an increased risk for cardiovascular disease in individuals infected with HIV.
Carotid artery plaque was predictive of mortality, with differences observed by sex and HIV serostatus.
Co-infection of HIV+ and tuberculosis (TB) may be associated with decreased neurological and neuropsychological functioning.
Inspection at the VIP Spa in Albuquerque detected practices that might spread HIV or hepatitis B and C.
Lopinavir/ritonavir-based treatment may be associated with higher total cholesterol in young children.
One patient achieved complete remission in the trial, while 5 other patients experienced partial remission.
The Aptima assay has 6-sigma performance, high concordance with the RealTime reference assay, and is user friendly and efficient, making it a good choice for laboratories that perform routine monitoring of HIV-1 viral loads.
Ibalizumab showed significant antiviral activity in patients with multidrug-resistant HIV-1 infection, advanced disease, and few other treatment options
Delstrigo is approved as a complete regimen whereas Pifeltro is to be administered in combination with other antiretrovirals.
A group-based behavioral intervention reduced the sexual risk for HIV infection and transmission by nearly 40% in young transgender women.
Patient navigation may be considered an effective strategy to enhance engagement and continuation in disease treatment among people with HIV.
Improvements seen in retention in care, CD4 counts, and viral suppression.
Lower odds of having detectable viral load for older adults and those using ISTI-based regimen
Anxiety sensitivity may explain the association between stigma and pain among people living with HIV.
Recommendations have been developed for addressing the HIV/AIDS epidemic in the African-American community.
Ibalizumab has antiviral activity among patients with multidrug resistant HIV-1 infection.
The ATLAS study enrolled 570 patients infected with HIV-1; participants were randomized to either the experimental or active comparator arms.
The FDA has approved labeling updates for Genvoya, Stribild and Tybost to include new drug-drug interaction data.
In a large, geographically diverse sample of patients engaged in routine HIV primary care, past HIV appointment attendance emerged as the most powerful predictor of future attendance.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- The Misuse of Antibiotics in Acute Pancreatitis Appears Widespread
- ART Reduces Neurocognitive Impairment in Patients Living With HIV
- Tackling the Challenges Associated With Treating Hepatitis C Infection in Pediatric Patients
- Mental Health Problems in Adolescents With HIV: Overview & Expert Interview
- Severity of Acute Respiratory Infections in Children Affected by Viral Etiology
- Antibiotic Prophylaxis Before Dental Procedures May Be Unnecessary
- Penicillin Allergies: Commonly Reported but Rarely Accurate
- Irritable Bowel Syndrome Treatments
- Oral Ciprofloxacin Effective in Treatment for Bacteremia
- Need for Adequate Screening for Infants With HCV Infected Mothers During Pregnancy
- Patient Develops Glandular Tularemia After Taking Care of Sick Cat
- Internet-Based Intervention Can Reduce Depression in People Living With HIV
- Prophylaxis With TMP-SMX Did Not Alter Risk for Non-UTI Infections
- Low Recurrence With Shortened IV Abx Course in GBS Bacteremia
- Renal-Replacement Timing Has No Effect in Kidney Injury, Sepsis